



Uscom

Uscom (UCM) – Global Medical Devices

Global growth

June 2016



Rob Phillips

PhD(med), MPhil(med), FASE, DMU(cardiol)

Associate Professor, Critical Care Research Group, School of Medicine, The University of Queensland

Uscom Executive Chairman/CEO

The Measure of Life

Disclaimer

This presentation is intended to provide a general outline only and is not intended to be a definitive statement on the subject matter. The information in this presentation, whether written or verbal, has been prepared without taking into account the commercial, financial or other needs of any individual or organisation.

While Uscom (the "Company") has taken due care in compiling the information, neither the Company nor its officers or advisors or any other person warrants the accuracy, reliability, completeness or timeliness of the information or guarantees the commercial or investment performance of the Company. Certain information may relate to protected intellectual property rights owned by Uscom. By viewing this presentation the viewer accepts the terms of the Company NDA. The information does not constitute advice of any kind and should not be relied on as such. Investors must make their own independent assessment of the Company and undertake such additional enquiries as they deem necessary or appropriate for their own investment purposes. Any and all use of the information is at your own risk.

Uscom

“Uscom has acquired global assets to ensure reliable revenue growth for investors for the coming decade.”

Summary

- Non-invasive cardiovascular pulmonary device manufacturer
- World leading technologies
- Global partners, nearing profitability (\pm \$3m revenue)
- Rapid growth (+40% for 4 years), before transformational revenue and partnerships
- Uscom BP+ and SpiroSonic for market and revenue FY 2017
- Transformational partnership with China CIIC – \$65m over 5 years
- Growth foundations set for the coming decade
- Annual results imminent
- Unrecognised investor value

Business Background

- Premium noninvasive cardiovascular and pulmonary monitoring devices
- Addressing the growing threat of superbugs, heart failure, hypertension and asthma
- Validated, clinically accepted, cost and life saving devices with critical applications
- Aggressive global growth strategy
- IP protected and FDA, CE and CFDA regulatory approvals
- Uscom BP+ and SpiroSonic for market FY 2017
- Transformational partnerships evolving

Corporate

- ASX listed (UCM)
- Headquartered in Sydney
- Market cap of \$28m
- 108m shares on issue
- Rob Phillips, Founder and CEO, holds 18% of company


Board & Management

- Rob Phillips, Chairman & CEO
- Sheena Jack, Director (HCF, Moneytime Health)
- Christian Bernecker, Director (Stream)
- David He, Director (J&J, McKinseys)
- Nick Schicht, General Manager

Financials

- Sales +59% 2015
- Revenue +48% 2015 (\$2+m)
- Cash consumption - \$1m
- Gross Margins ~ 78%
- Cash ~ \$2.7m

Strategic growth



Three world leading technologies merged under one operating entity

Debt free acquisitions – scrip, raising and operations

Rapidly strengthening balance sheet

Acquisitive, strategic and diversified entity

Scientific, operational and strategic synergy

New product suites developed and funded from operations

UK entity founded, Hungarian manufacturing integrated

Preparing to market and volume manufacture BP+ and SpiroSonic

New revenue streams - BP+ and SpiroSonic in 2017

Uscom Recognition

Company of the Year, 2014

Johnson & Johnson Innovation Industry Excellence Awards

“A milestone driven, rapidly growing global medical device company, with real products, real revenue, real growth and an aggressive growth strategy”

Johnson & Johnson INNOVATION

AusBiotech
AUSTRALIA'S BIOTECHNOLOGY ORGANISATION

Products and Market

Multiple high fidelity noninvasive digital medical devices



Fluid, Sepsis & Heart Failure

- US 1.3bn market *
- CAGR of 7.6% *
- CE, FDA, TGA, CFDA

USCOM 1A

Cardiac Output Monitoring




Hypertension & Vascular Health

- US 1.7bn market *
- CAGR of 11.5% *
- CE, FDA, TGA

BP+

Blood Pressure Monitoring



COPD & Asthma

- US 400m market *
- CAGR of 6.5% *
- CE, TGA, FDA

SpiroSonic

Pulmonary Monitoring



Products - USCOM 1A

Heart failure, hypertension, sepsis, fluid
Non invasive, accurate, compact, platform technology

Accurate cardiac output

Cardiac stroke volume

Systemic vascular resistance

Left + right heart measurement



Works with all other hospital equipment

Intuitive touch screen


Real time data

Platform technology with multiple uses

Non invasive, real time, beat-to-beat haemodynamics

Uscom – Devices the experts use

Products - Uscom BP+



Hypertension, heart failure and vascular disease
Central Blood Pressure and Pulse Wave Analysis
The new standard for hypertension

- FDA, CE Mark, TGA approvals
- Supra-systolic Oscillometry
- Reliable and accurate
- Central and Brachial BP
- Replaces sub-systolic methods (cuff)



- Home or clinic
- PPW Analysis
- Results in 30 seconds
- No training required
- Platform technology with multiple uses


Stand alone, non invasive, accurate, compact system with BP+Reporter

Uscom – Devices the experts use

Products - Uscom SpiroSonic

Asthma, COPD, Occupational Lung Disease and drug compliance monitoring

- High fidelity digital ultrasonic spirometry
- Multi-path ultrasonic sensing
- FDA, CE, and TGA approvals
- Reliable and accurate
- Auto calibration
- Research, home and clinic
- Wireless transmission
- SpiroReporter analysis software
- FloFree tube – low resistance
- Software guided examination and report
- Simple disinfection
- Platform sensors with medical and industrial applications



Stand alone, non invasive, accurate, compact system with SpiroReporter

Uscom – Devices the experts use

Big Data

***Big data needs high quality sensors
Uscom specialises in high quality non-invasive sensors***

- Software analytics
- Telemetric signals
- Cloud based processing/diagnosis
- Personalised clinical advice
- Medication and dosage
- Serial monitoring
- Multiple measures
- Home care market
- Subscription service model
- Global partner opportunities – China, US, Euro
- Multiple software providers – few hardware providers



Stand alone, wireless, accurate, compact, digital devices

Uscom – Devices the experts use

New - tSpiro

Uscom selling technologies others are researching
 High fidelity telemetric spirometer
 The future for asthma and COPD

- CE, FDA and TGA. CFDA in train
- US revenue (more than 400)
- Software analytics
- Telemetric signals to cloud via iphone
- Cloud based processing/diagnosis
- Connecting patients to clinicians
- Personalised clinical advice - medication and dosage
- Serial monitoring
- Multiple measures
- Home care market
- Capital and subscription revenue
- Global partners – China, US, Euro
- Multiple software providers – few hardware providers

SpiroSonic 
MOBILE




“Addressing the challenges of Asthma, COPD and Occupational Lung Disease”

High fidelity digital ultrasonic spirometry – setting the standards in pulmonary care.

SpiroSonic Mobile is a pulmonary function diagnostic monitoring device. It is a compact and mobile solution for use by pulmonologists, general practitioners and patients.



Pulmonary Diagnostics Software



- Multi path ultrasonic sensors
- FreeFlo tube - low resistance, no turbines or mesh
- FDA Clearance, CE, and TGA approvals
- Reliable and accurate
- Auto calibration
- Software guided examination and report
- Research, home and clinical applications
- Simple disinfection

Uscom Limited

info@uscom.com.au
 +612 9247 4144
 www.uscom.com.au

The measure of life

Patent pending. Uscom, the SpiroSonic logo and FreeFlo are trademarks of Uscom Limited. All other trademarks are the property of their respective owners. © 2012 Uscom Limited. All rights reserved.



New SpiroSonic Series

Improved diagnosis, management and monitoring of pulmonary diseases
tSpirometers - high fidelity telemetric pulmonary monitoring

SPIROSONIC FLO Ultrasonic Spirometer



"Addressing the challenges of Asthma, COPD and Industrial Lung Disease"

High fidelity digital ultrasonic spirometry – setting the standards in pulmonary care.
SpiroSonic Flo is a pulmonary function diagnostic monitoring device. It is a compact, PC compatible solution for use by pulmonologists, general practitioners and patients.



- Dual path ultrasonic sensing
- FreeFlo tube - low resistance, no turbines or mesh
- FDA Clearance, CE, and TGA approvals
- Reliable and accurate
- Auto calibration
- Software guided examination and report
- Research, home and clinical applications
- Simple disinfection



Pulmonary Diagnostics Software

The measure of life

Uscom Limited
info@uscom.com.au
+612 8267 4144
www.uscom.com.au

SPIROSONIC SMART Handheld Software Guided Spirometer



"Addressing the challenges of Asthma, COPD and Industrial Lung Disease"

High fidelity digital ultrasonic spirometry – setting the standards in pulmonary care.

SpiroSonic Smart is a compact, touch-screen, Li-Ion battery operated solution for use by pulmonologists, general practitioners and patients.



- Multi-path ultrasonic sensing
- FreeFlo tube - low resistance, no turbines or mesh
- FDA Clearance, CE, and TGA approvals
- Reliable and accurate
- Auto calibration
- Software guided examination and report
- Research, home and clinical applications
- Simple disinfection



Additional options:
• Wireless Thermoprinter (handheld)
• Integrated Flow Optimiser
• SpiroReporter Software

The measure of life

Uscom Limited
info@uscom.com.au
+612 8267 4144
www.uscom.com.au

SPIROSONIC PRO Stand-alone Comprehensive Pulmonary Diagnostic Station



"Addressing the challenges of Asthma, COPD and Industrial Lung Disease"



- Dual path ultrasonic sensing
- FreeFlo tube - low resistance, no turbines or mesh
- FDA clearance, CE, and TGA approvals
- Reliable and accurate
- Auto calibration
- Wireless connectivity
- Software guided examination and report
- Research, home and clinical applications

Image simulated. Not purchased with SpiroSonic Model

SpiroSonic Pro is a complete stand-alone Diagnostics Desktop Station. It can be connected to SpiroSonic Flo and SpiroSonic Mobile via USB or Bluetooth. SpiroSonic Pro features a large touchscreen, an optional Integrated Thermo Printer and the SpiroReporter Software. All measurements are archived into an integrated database for reporting.


The measure of life

Uscom Limited
info@uscom.com.au
+612 8267 4144
www.uscom.com.au

SpiroSonic SPIROREPORTER



"Addressing the challenges of Asthma, COPD and Occupational Lung Disease"



- Digital patient archive and SpiroSonic image storage system
- Display and analysis of SpiroSonic respiratory flow volume curves
- Multi-parametric SpiroSonic trend displays
- Configurable patient report for printing and exports
- Connectivity to most MRSs
- Multi-language support
- Software guided decision support

Advanced pulmonary diagnostics software

High fidelity digital ultrasonic spirometry – setting the standards in pulmonary care.

The measure of life

Uscom Limited
info@uscom.com.au
+612 8267 4144
www.uscom.com.au

For launch FY 2017

Uscom – Devices the experts use



Regulatory

Uscom is preparing a new generation of products for regulatory approval across multiple jurisdictions for marketing in 2017

	USCOM 1A	BP+	Uscom BP+	Thor	SpiroSonic
CE (Europe)	✓	✓	Preparation	✓	Preparation
FDA (USA)	✓	✓	Preparation	✓	Preparation
CFDA (China)	✓	-	Preparation	-	Preparation
TGA (Aus)	✓	✓	Preparation	✓	Preparation



Uscom – Devices the experts use

BioTechnology Leader



	Uscom	BP+	Thor
Granted	12	21	3
Pending	4	1	1

Patents - Real IP, real value, product pipeline

Uscom – Devices the experts use

De-Risked Technology

Featured in 500+ peer reviewed publications and presentations



Sepsis, Heart failure, Hypertension, Fluid management, Emergency, Pediatrics, Cardiac transplantation, Electrophysiology, Emergency transport, Anesthesia, Liver transplantation, ICU, Pre-eclampsia, Pulmonary hypertension, Nurse outreach, Organ procurement, Haemodialysis, Neonates, infants, Children etc.....

Uscom – Devices the experts use

Multi-Products

Three world leading product ranges entering profit phase


	Concept	Product	Pilot	Validation	Regulatory	Revenue	Global Distribution	Profit FY17
USCOM 1A	✓	✓	✓	✓	✓	✓	✓	±✓
Uscom BP+	✓	✓	✓	✓	✓	✓	✓	±✓
SpiroSonic	✓	✓	✓	✓	✓	✓	✓	✓



IP transformed into profit

Revenue Targets

Total Revenue



SpiroSonic – FY 2017



BP+ - FY 2017



■ SpiroSonic
■ BP+
■ USCOM


USCOM



\$20m revenue by 2020 = 5 year CAGR of 58%

The Future


Value Cascade



Converting off balance sheet assets to revenue.

Global Operations

1. Uscom Aus
2. Uscom UK
3. Uscom Budapest
4. Uscom USA
5. Uscom Shanghai



Key Markets

- 1/5. AsiaPAC
- 2/3. Europe
4. Nth America


Focus FY 2017

Asia – Establish CIIC
US – BP+ and SpiroSonic release
Global tSpiro partnerships

China Growth

**David He joins UCM Board
Formerly J&J China,
McKinsey Shanghai**

China Health Expenditure as % of GDP



China Health Spend (USD)


GDP=12,000,000,000,000
 Health=5.4%=648,000,000,000
 Objective=12%=1,400,000,000,000
Growth(+6.6%)=\$792,000,000,000

Uscom China Targets (USD)

Population = 1.35b
 3 provinces < 10% pop = \$10m
 31 Provinces = 100%
 10 x current UCM revenue = \$10m
 2 new products = \$20m
Total revenue China = \$30m USD

Uscom positioning to grow with China - \$30m pa revenue target

News - Uscom CIIC China



Jillian Skinner MP
Page Liked · 4 hrs · 🌐

It was a pleasure to join Prof Rob Phillips, Chief Executive Officer of ASX listed company Uscom and Wenan Zhu, General Manager of Shanghai CIIC Science and Technology Development following their signing an agreement expected to generate \$30 million in sales over the next five years.
Prof Phillips was a member of the strong team of health leaders who accompanied me on a trade visit to China in April.
The partnership will help market the Australian designed cardiovascular and pulmonary health devices in China.
This is another terrific example of the benefits to be gained for our high quality, globally recognised inventors developing export partnership into the huge Chinese market to the advantage of patients everywhere.
Pictured here with Prof Phillips and Wenan Zhu.



Five year importation and wholesale agreement with Shanghai CIIC Science and Technology Development Corp targeted to generate USD\$48.2m (≈A\$65m) in sales.



CIIC S&T – State owned company
CIIC revenue – \$10b USD, Med Device Division \$250m USD



CIIC China




“We plan to make Uscom one of the leading medical device brands in China over the next five years.”

Daniel Sun, Head of BD and Marketing, Shanghai CIIC Science and Technology, Medical Device division

Shareholder value, if targets achieved - \$1.40 per share.

(\$13m sales, \$6m costs, profit \$7m, PE x 20, 108m shares)

Increasing recognition



Alan Kohler

Peter Switzer
Fox TV

CNBC Asia

With improved operational performance has come increased media and international investor interest

Increasing recognition

BUSINESS

Uscom on the cusp of greatness

EXCLUSIVE

SARAH-JANE TASKER
HEALTHCARE

Australian medical device company Uscom has pushed through a domestic start-up environment that is littered with more death stories than tales of survival, and is on the verge of what founder Rob Phillips says is a "major transformation".

Mr Phillips, executive chairman of the developer of cardiac, vascular and pulmonary monitoring devices, has plans to turn the \$20 million company — it counts the International Space Station as a customer — into a \$1 billion stock.

"We started in cardiovascular pulmonary because that is what I know. I've spent my whole life developing concepts, ideas and mathematics around physiology. That's my love and life."

He said when he started Uscom people told him it was a great idea but would never work.

Fast forward to today and Mr Phillips says the company, which has made two acquisitions and is rapidly expanding its global reach, is on the cusp of a major transformation.

"Things are changing quickly for us. There was about 15 years of clinical and research work that was followed by 15 years of direct work in the company. These things don't just happen, you in-



BRAD HUNTER

Rob Phillips says manufacturing in Australia is harder than anywhere else

THE AUSTRALIAN

With improved operational performance has come increased media and international investor interest

The Australian, 5-3-16
Sarah-Jane Tasker

Current objectives

- *Realise CIIC targets*
- *Maintain USCOM 1A growth*
- *Deliver BP+, BP+Reporter, SpiroSonic and SpiroReporter to worldwide markets (products, regulatory and manufacturing)*
- *Continue partnership discussions*
 - *Distributors with high reach and reputation*
 - *Develop specific application distribution – eHealth, maternal health, paediatric sepsis, etc.*
- *Consolidate global entity and operations*
- *Manage rapid growth*


Operational risks

- Global medical markets unpredictable
- Product development/regulatory slower and more costly than expected
- Distribution slow to achieve revenue goals and integrate new products
- Costs for acquisitions, product development and production in advance of revenue
- Competition risks and patent breaches – difficult to predict and monitor competitors
- Complexity of operating in multiple jurisdictions – China, US, UK, Hungary, Australia
- Preserving current revenue growth as new products developed for market
- International accounting & auditing expensive, complex and time consuming
- New product lines and new marketing – time to learn
- Transitioning Budapest to volume manufacture


UCM – Growth trend

A blue sky story with de-risked operations

UCM Revenue and Income




UCM Distribution Agreements



*Current revenue from USCOM 1A
BP+ and SpiroSonic revenue in FY 2017*

UCM – Growth trend

Revenue and Income



2016 - Revenue + cash receipts continue to rise (40±% for 4 years)

Share price +77%

Transformational CIIC deal and new products yet to be accounted by market

Right company, right time.....

Profitability?

Revenue rising 40% YOY for last 4 years

Margins 60-80%

2016 YOY cash receipts rising:

Q1 up 133%, H1 up 71%, Q3 up 112%

Q3 cash outflow \$55k (near breakeven)

2016 costs include once off costs:

Thor acquisition (\$700k)

Integration of Thor - audit, restructure and reporting


Regulatory preparation for BP+ and SpiroSonic

Marketing and distribution

Transformational CIIC deal for \$15m pa (6m costs - \$7m pa profit)

New global deals in discussion


UCM Quarterly Cash Receipts



Right company, right time.....

Right Sector - Long Term Growth

ASX 10 yr CAGR % pa




UCM sales growth
2014 – 67%
2015 – 59%

- 1st Feb 2006 – 1st Feb 2016
- Exclusive of dividends

Healthcare, right sector.....


Right Time for Growth

Revenue Growth % pa



Right company, right time.....

UCM outperforms market



belldirect >

2016 year to date performance.....



Uscom

- Value investment ✓*
- Experienced management ✓*
- Strong underlying business ✓*
- Strong growth phase ✓*
- Invested in growth ✓*
- Premium global markets ✓*
- Diversified and lifesaving technologies ✓*
- Aggressive global growth strategy ✓*
- Two new product ranges for market in the next 12mths ✓*
- Right time – 2016 results imminent ✓*

Uscom

“Uscom has acquired global assets to ensure reliable revenue growth for investors for the coming decade.”



Uscom

Uscom (UCM) – Global Medical Devices

Global Growth

June 2016

Thank You

Rob Phillips

PhD(med), MPhil(med), FASE, DMU(cardiol)

Associate Professor, Critical Care Research Group, School of Medicine, The University of Queensland

Executive Chairman/CEO

Uscom – Medical devices the experts use

USCOM 1A Competitive Advantage

Method	Manufacturer	Technology	Rel+Rep	Non-invasive	Simple	Cost	Portable	SV beat to beat
USCOM 1A	Uscom	Doppler	✓	✓	✓	✓	✓	✓
BioZ	Samsung	BioImpedance	✗	✓	✓	✗	✓	✗
NiCOM	Cheetah	BioReactance	✗	✓	✓	✗	✓	✗
Nexfin	Bmeye	APP	✗	✓	✓	✓	✓	✗
CardioQ	Deltex	Doppler	✓	✗	✓	✗	✓	✗
LiDCO	LiDCO	LiCl dilutio +APP	✓	✗	✗	✗	✗	✗
LiDCOrapid	LiDCO	APP	✗	✗	✓	✗	✗	✗
PiCCO (mod Tx + PP)	Pulsion	APP	✓	✗	✗	✗	✗	✗
FloTrac	Edwards	APP	✗	✗	✗	✗	✗	✗
PAC (Tx)	Many	Thermodilution	✗	✗	✗	✗	✗	✗

Testimonials

*“This machine is **saving lives**, there are no two ways about it.”*

Professor Brendan Smith, Anesthetist, Intensivist and Emergency Physician, N.S.W. Dept of Health, Australia

*“USCOM has changed the way I look at the cardiovascular status of my patients. It’s part of the initial shock evaluation and monitored regularly thereafter.... USCOM has now been established as the **standard of care**.”*

Dr Akash Deep, Director of Paediatric ICU, King's College Hospital, London

*“The USCOM device is a simple method of accurately and noninvasively measuring central circulation, a **goal of cardiology** for many years. The device has the potential to change the way we approach management of sepsis, heart failure and hypertension.”*

Professor Malcolm West, Cardiologist, Mayne Professor of Medicine at The University of Queensland School of Medicine, Brisbane, Australia and Uscom Medical Advisory Board Member.

*“I have used USCOM for over 5 years now on our very sick children, and use it to guide management. We are now beginning multi-centre, global research which will define the way USCOM is **used in Paediatric Departments across the world**.”*

Dr Joe Brierley, Consultant Intensivist, Great Ormond Street Hospital for Sick Children, London, UK.

*“The USCOM device is really good; I use it in all my anaesthetics. I think **there should be one on every ICU bed and on every anaesthetic patient**.”*

Dr Steve Woodford, Consultant Anaesthetist, circulatory researcher at Australian School of Advanced Medicine, and Uscom Investor,

*“To parents and doctors this machine, **USCOM, is priceless**. This machine is thought to have saved baby Abbie’s life.*

BBC Documentary “New machine helps save babies life”, 2010, Nottingham Children’s Hospital

Uscom – Medical devices the experts use



BP+ Competitive Advantage



Uscom BP+	TensioMed	BPLab	IEM	Centron	AtCor
Australia	Hungary	Russia	Germany	UK	Australia
USD 3,500	USD 6,000	USD 7,000	USD 7,000	USD 6,300	USD 20,000
1 min	2 min	2 min	2 min	1 min	1 min
Stand-alone	ABP, needs computer	ABP, needs computer	ABP, needs computer	Stand-alone	Needs computer
CE, FDA, TGA	CE	CE	CE, FDA	CE	CE, FDA
Aortic + brachial waveform	Central systolic BP	Rough waveform	Rough waveform	Rough waveform	Rough waveform
Physical model	Statistical regression	Transfer function	Transfer function	Transfer function	Transfer function

Uscom – Medical devices the experts use

Why ?

Independent research from Cambridge University, Weill Cornell, University of California, Wales Heart Institute – BP+ = Four stars

Table 1 Indirect, non-invasive methods for estimating central pressure

Method of waveform recording	Device	Company	Method of calibration	Method of estimation	Clinical applicability [†]
Radial tonometry	BPro ^{66,67}	HealthSTATS	Brachial–radial cuff BP	GTF (radial-aortic)	++
	SphygmoCor ^{12,88}	AtCor Medical	Brachial–radial cuff BP	(i) GTF (radial-aortic)	+
				(ii) Late systolic shoulder	+
Brachial cuff PVP	HEM9000AI ^{39,77}	Omron	Brachial cuff BP	(i) Algorithm	++
				(ii) Late systolic shoulder	++
	*ARCSolver ^{89,90}		Brachial cuff BP	GTF (brachial-aortic)	+++
	Centron cBP301 ^{35,91}	Centron Diagnostics	Brachial cuff BP	GTF (brachial-aortic)	++++
	Vicorder ⁹²	Skidmore Medical	Brachial cuff BP	GTF (brachial-aortic)	+++
Suprasystolic brachial cuff PVP	XCEL	AtCor Medical	Brachial cuff BP	GTF (brachial-aortic)	+++
	Method of Sung et al. ⁴²		Brachial cuff BP	Algorithm	++
	Arteriograph ^{37,93}	TensioMed	Brachial cuff BP	Late systolic wave amplitude	+++
	Cardioscope II ^{36,94}	Pulsecor	Brachial cuff BP	Algorithm	++++

PVP, pulse volume plethysmography; GTF, generalized transfer function.


*Incorporated in Mobil-O-Graph PWA device (IEM GmbH).

[†]Personal view based on experience, operator-dependency, need for computer/software interface, with + indicating limited applicability to routine clinical practice and ++++ indicating high applicability.



BP+ is on the international space station

SpiroSonic Competitive Advantage



Uscom SpiroSonic	Welch Allyn	Schiller	Sibelmed	Vitalograph	MIR	Carefusion	NDD
Australia	USA	Switzerland	Spain	USA	Italy	USA	Switzerland
SpiroSonic	SpiroPerfect	Spirovit SP-1	Dataspir Touch	Pneumotrac	Spirodoc	Microloop	EasyOne PLus
USD 1,890	USD 2,100	USD 1,850	USD 2,300	USD 2,030	USD 1,580	USD 2,180	USD 1,990
Dual Path Ultrasound	Diff Pressure	Diff Pressure	Turbine	Diff Pressure	Turbine	Turbine	Single Path Ultrasound
Accurate Auto calibration SpiroReporter Fully digital FreeFlo sensor Hygeinic SpO2 Bluetooth Rechargeable	Multiple iterations	Multiple iterations	Multiple iterations	Multiple iterations	Multiple iterations Consumable turbines	Multiple iterations	Accurate Consumable tube

Uscom – Medical devices the experts use

CPT Codes and Re-Imbursement

Product	Measure	Region	Code	Price (AUD)	Status
Uscom BP+	Central BP	USA	93050	\$25.60	S*
USCOM 1A	Cardiac Output	USA	76999	\$107.00	S**
	Cardiac Output	China	310701023	\$44.00	✓
	Cardiac Output	China	220600010	\$13.50 + \$2.50 measure	✓
	Cardiac Output	Australia	TBD	TBD	S**
Uscom Thor	Spirometry	USA	94010	\$51.43	✓
	Spirometry	USA	94060	\$87.14	✓
	Spirometry	USA	94070	\$87.00	✓
	Spirometry	USA	94375	\$57.14	✓
	Spirometry	Australia	11506	\$20.55	✓
	Spirometry	Australia	11509	\$35.65	✓
	Spirometry	Australia	11512	\$61.75	✓

S* Subject to Software modification and FDA notification

S** Under submission

TBD –To be determined